Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis

Table 1 Descriptive statistics of patients with and without small intestinal bacterial overgrowth

	Patients with SIBO (n = 24)	Patients without SIBO (n = 23)	P value
Age, yr	50 (39-59)	51 (37-58)	0.949
Male/female	12/12	11/12	0.557
Body mass index, kg/m2	25.0 (22.9-27.8)	24.1 (22.3-26.1)	0.302
Red blood cells, 1012/L	3.7 (3.3-4.2)	4.0 (3.6-4.3)	0.322
White blood cells, 109/L	3.6 (2.6-4.9)	4.0 (3.2-5.6)	0.437
Platelets, 109/L	78 (49-108)	90 (59-115)	0.229
C-reactive protein, mg/L	11.4 (1.6-17.1)	2.1 (0.1-9.2)	0.025
Serum albumen, g/L	35 (31-40)	36 (31-41)	0.617
Serum total bilirubin, μmol/L	36 (27-54)	38 (23-64)	0.848
Prothrombin (Quick test), %	57 (50-68)	64 (53-70)	0.233
Ascites, n (%)	17 (70.8)	10 (43.4)	0.054
Esophageal varices, n (%)	19 (79.2)	19 (82.6)	0.528
Spleen length, cm	16.2 (14.0-20.0)	14.6 (13.3-16.2)	0.080
Portal vein diameter, mm	13.0 (12.0-13.7)	12.0 (11.0-13.5)	0.263
Overt hepatic encephalopathy, n (%)	9 (37.5)	8 (34.8)	0.544
Child-Pugh score	8 (6-10)	8 (6-9)	0.551
Drugs used by patients within 6 mo prior to study enrollment
Proton pump inhibitors, n (%)	9 (37.5)	8 (34.8)	0.544
Beta blockers, n (%)	5 (20.8)	3 (13.0)	0.375
L-ornithine-L-aspartate, n (%)	4 (16.7)	4 (17.4)	0.625
Diuretics, n (%)	13 (54.2)	8 (34.8)	0.149
Ursodeoxycholic acid, n (%)	4 (16.7)	5 (21.7)	0.471
Glucocorticoids, n (%)	2 (8.3)	6 (26.1)	0.109
Antiviral drugs, n (%)	7 (29.2)	4 (17.4)	0.273

SIBO: Small intestinal bacterial overgrowth.